At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 85 enrolled
Drug / intervention
indacaterol and glycopyrronium bromide (QVA149) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Blinded, Double Dummy, Multi-center, Placebo Controlled, 3 Period, Crossover Study to Assess the Effect of QVA149 (110/50 µg o.d.) on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control.
In Brief
A Phase 3 clinical trial evaluating indacaterol and glycopyrronium bromide (QVA149), placebo, and 1 other intervention for COPD. Completed, enrolled 85 participants across 13 sites in 2 countries.
Detailed Summary
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesGermany, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedFeb 11, 2011
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.4 years ago
Interventions
indacaterol and glycopyrronium bromide (QVA149)drug
placebodrug
tiotropiumdrug